Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Label, Phase 1B Study of Escalating Doses of RO5045337 Administered Orally, With Cytarabine Administered A) Subcutaneously, or B) Intravenously, in Patients With Acute Myelogenous Leukemia (AML)

NCT01635296 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01635296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01635296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Label, Phase 1B Study of Escalating Doses of RO5045337 Administered Orally, With Cytarabine Administered A) Subcutaneously, or B) Intravenously, in Patients With Acute Myelogenous Leukemia (AML)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2012
Completion date
October 31, 2013
Enrollment
43 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

myelogenous leukemia, acute